



Harvey Pass

Harvey I. Pass, M.D joined NYU Langone Medical Center in 2005 as Professor of Cardiothoracic Surgery and Surgery, and the first Division Chief of Thoracic Surgery/Thoracic Oncology at NYU School of Medicine. His previous positions include Chief, Thoracic Oncology at the Karmanos Cancer Institute, Detroit, affiliated with Wayne State University, and he was the Head of the Thoracic Oncology Section of the National Cancer Institute for the National Institutes of Health in Bethesda, Maryland from 1986 to 1996. He is an internationally recognized expert in lung cancer and mesothelioma, and has maintained extramural funding from the Department of Veterans Affairs and the National Cancer Institute for his translational laboratory since 1998. He is presently funded by the Early Detection Research Network for the **Mesothelioma Biomarker Discovery Laboratory**, the Center for Disease Control for the **Mesothelioma Virtual Tissue Bank**, and by the NCI for the Program Project entitled **Pathogenesis of Mesothelioma**.

Dr. Pass received his B.A. from Johns Hopkins University and his M.D. from Duke University. He completed his surgical residency at Duke and University of Mississippi. He completed his residency in Cardiothoracic Surgery at the Medical University of South Carolina. Dr. Pass also completed a fellowship in Thoracic Oncology at the National Cancer Institute at the National Institutes of Health in Bethesda, Maryland.

Dr. Pass has published over 300 manuscripts in peer-reviewed journals, including *The New England Journal of Medicine* regarding the discovery of osteopontin as a possible early detection biomarker for mesothelioma. He is the lead editor on all four editions of the reference text *Lung Cancer: Principles and Practice*. He is co-editor of both editions of *Surgery: Basic Science and Clinical Evidence*, and *Oncology: An Evidence Based Approach*, and has also edited *Malignant Mesothelioma: Advances in Pathogenesis, Diagnosis, and Translational Therapies* and *100 Questions & Answers about Mesothelioma*. He is Associate Editor for the *Journal of Thoracic Oncology*, Surgical Editor for *Clinical Lung Cancer*, and a member of the editorial board for *Clinical Cancer Research*. He is presently on the Board of Directors for the **International Association for the Study of Lung Cancer**, the **International Mesothelioma Interest Group**, and the **Lung Cancer Alliance**